Other eligibility criteria include tumor tissue provided for central analysis of PD-L1 expression (Dako PD-L1 IHC 28-8 pharmDx), no prior therapy for melanoma (except surgery and/or adjuvant radiation for CNS lesions), and no prior immunotherapy. The gene discussed is CD274; the disease is neoplasm.